Silo Pharma, Inc. (NASDAQ: SILO) is enjoying a pre-market spike following a significant license agreement, indicating increased investor interest. The business has obtained an exclusive global license to further the research, development, and commercialization of its Alzheimer’s medication, SPC-14.
Addressing Critical Medical Needs
The exclusive licensing of SPC-14 positions Silo Pharma to address a significant gap in medical treatment. Early pre-clinical studies suggest that SPC-14 may mitigate stress and improve cognitive function, offering potential relief to numerous patients and families.
Market Expansion and Strategic Initiatives
The global market for Alzheimer’s disease therapeutics is projected to surpass $30.8 billion by 2033, with an expected compound annual growth rate (CAGR) of 18.8% from 2024 to 2033. This growth is driven by an increasing prevalence of the disease among aging populations and ongoing advancements in neuroscience research.
Diversification into Stress-related Disorders
Alongside SPC-14, Silo Pharma has recently announced a parallel exclusive licensing agreement for its leading candidate, SPC-15. This intranasal therapy for stress-induced emotional disorders and PTSD was created in conjunction with Columbia University and will be further researched, manufactured, and commercialized.
Silo Pharma has filed a pre-IND briefing package and meeting request to the United States Food and Drug Administration (FDA) for SPC-15. The business is in the final stages of filing an Investigational New Drug (IND) application to begin first-in-human clinical studies. Silo Pharma intends to take advantage of the FDA’s expedited approach for SPC-15, as it did with SPC-14, in order to accelerate clinical timeframes and lower development costs.
Strategic Milestone and Market Performance
The execution of the exclusive licensing agreement for SPC-15 represents a significant milestone for Silo Pharma, potentially enhancing shareholder value pending FDA approval. According to the most recent pre-market findings, SILO stock has risen 123.36% on the US stock charts, hitting a trading price of $2.39.
This complete strategy demonstrates Silo Pharma’s strategic commitment to creating breakthrough neurology medicines, allowing the business to capitalize on shifting market possibilities and contribute to better patient outcomes throughout the world.
